A Randomized, double-blind, placebo-controlled, two-way crossover trial to compare Moxifloxacin induced QT interval prolongation in Japanese and Korean healthy subjects

Trial Profile

A Randomized, double-blind, placebo-controlled, two-way crossover trial to compare Moxifloxacin induced QT interval prolongation in Japanese and Korean healthy subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Dec 2016

At a glance

  • Drugs Moxifloxacin (Primary)
  • Indications Acute exacerbations of chronic bronchitis; Acute sinusitis; Bacterial infections; Community-acquired pneumonia
  • Focus Adverse reactions
  • Most Recent Events

    • 01 Dec 2016 Results assessing effect of moxifloxacin on QT interval prolongation published in the Clinical Therapeutics.
    • 13 Jun 2013 Status changed from recruiting to completed, according to ClinicalTrials.gov.
    • 13 Jun 2013 New source identified and integrated: ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top